Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 12/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 12/20 | 0.40 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 3/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31068225 | 1.00 | DDB1 (0.40) | DDB1CRBNPDCD1LG2CD274OPRM1 | |
| SCHEMBL31068362 | 0.87 | CNR2 (0.40) | DDB1CRBNPDCD1LG2CD274OPRM1 | |
| SCHEMBL29348645 | 0.87 | CRBN (0.39) | DDB1CRBN | |
| SCHEMBL29348585 | 0.87 | CNR2 (0.40) | DDB1CRBNPDCD1LG2CD274OPRM1 | |
| SCHEMBL29348598 | 0.85 | DDB1 (0.39) | DDB1CRBNPDCD1LG2CD274NPY5R | |
| SCHEMBL31068207 | 0.85 | DDB1 (0.39) | DDB1CRBNPDCD1LG2CD274NPY5R | |
| SCHEMBL31068116 | 0.85 | CNR2 (0.47) | DDB1CRBNCNR2 | |
| SCHEMBL29348644 | 0.85 | CNR2 (0.47) | DDB1CRBNCNR2 | |
| SCHEMBL29348472 | 0.82 | CRBN (0.43) | DDB1CRBN | |
| SCHEMBL31068184 | 0.80 | DDB1 (0.39) | DDB1CRBNPDCD1LG2CD274OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |